Author Archives: David Melamed, PhD

Trikafta Soon Be Up for Approval, Cystic Fibrosis Canada Reporting

Following yearlong advocacy efforts, the triple-combination therapy Trikafta is expected to soon come up for approval before Health Canada, the country’s health regulatory agency, the non-profit patient group Cystic Fibrosis Canada has announced on its website. Vertex Pharmaceuticals, which developed and markets Trikafta, its newest modulator therapy for cystic fibrosis and…

How Trefoil Proteins Act to Thicken Mucus Detailed in Study

Researchers identified a biochemical mechanism that regulates the thickness of mucus, and could serve as a target of new treatments for chronic respiratory illnesses that include cystic fibrosis (CF). The study, “Trefoil factors share a lectin activity that defines their role in mucus,” was published in the journal …


Featured Column

The Benefits of Being Sick

A banner for Lara's column, depicting a car on a road trip winding through a forest.
As columnist Lara Govendo reflects on her journey through CF and transplant, she realizes there are a surprising number of benefits.

Read the Column


Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.